USA flag logo/image

An Official Website of the United States Government

Production of human CD39 as an antithrombotic agent

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70949
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
HL076053
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APT THERAPEUTICS, INC.
4041 Forest Park Avenue SAINT LOUIS, MO -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Production of human CD39 as an antithrombotic agent
Agency: HHS
Contract: 1R43HL076053-01
Award Amount: $98,750.00
 

Abstract:

DESCRIPTION (provided by applicant): Production of a human apyrase protein as an antithrombotic agent is proposed. Thrombotic vascular occlusion due to abnormal platelet aggregation can lead to many diseases, including ischemic stroke, myocardial infarction, and restenosis after angioplasty or bypass surgery. Many of the current anti-platelet or fibrinolytic agents are undesirable due to the lack of specificity, narrow time window of administration, or severe adverse effects. Human ecto-apyrase has recently emerged as a critical endothelial thromboregulator with outstanding premise as an anti-platelet drug. The apyrase metabolizes extracellular ADP released by activated platelets, thereby inhibiting platelet aggregation and recruitment. We have cloned the human apyrase and expressed its extracellular domain in mammalian cells. Our recombinant apyrase exhibits an outstanding ADPase activity in vitro. We plan to integrate cutting edge technologies to create a robust CHO-cell based expression system suitable for large-scale production and efficient purification of biologically active recombinant proteins. We expect this research to provide an advanced system for producing the apyrase, and other proteins of therapeutic importance, at a substantially reduced cost, thus creating a reliable source of protein necessary for pre-clinical/clinical studies.

Principal Investigator:

Soonseog Jeong
3148128112
SJEONG@NIDUSCENTER.COM

Business Contact:

Ridong Chen
3148128054
RCHEN@NIDUSCENTER.COM
Small Business Information at Submission:

APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC. 893 N WARSON RD ST. LOUIS, MO 63141

EIN/Tax ID: 431947715
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No